Glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell and applications thereof

TW202626743APending Publication Date: 2026-07-01CHIMIGEN BIOMEDICAL (CHENGDU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115109050
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-30
Filing Date
2024-06-28
Publication Date
2026-07-01
Patent Text Reader

Abstract

This application provides a glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and use thereof. A first aspect of this application provides a glycosyl-modified fusion protein including a murine Fc variant and a polypeptide antigen, where the murine Fc variant is obtained by subjecting a murine Fc fragment to amino acid mutation and non-mammalian glycosylation-modification; the murine Fc variant includes at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330 and glutamic acid at position 332; the non-mammalian glycosylation-modification excludes sialic acid-modification; the position numbering is performed according to the EU numbering system; the fusion protein binds to dendritic cells and activates the dendritic cells, including the proliferation and activation of specific T cells.
Need to check novelty before this filing date? Find Prior Art